Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ether. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL422163 | 0.90 | ALDH1A1 (0.40) | ALDH1A1TSHRTHRB | |
| Ether SCHEMBL3794585 | 0.89 | ALDH1A1 (0.37) | ALDH1A1THRB | |
| Ether SCHEMBL96502 | 0.89 | — | — | |
| Ether SCHEMBL8089271 | 0.89 | ALDH1A1 (0.37) | ALDH1A1THRB | |
| Ether SCHEMBL3701280 | 0.89 | ALDH1A1 (0.37) | ALDH1A1THRB | |
| Ether SCHEMBL2837591 | 0.89 | ALDH1A1 (0.37) | ALDH1A1THRB | |
| Ether SCHEMBL9058622 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRTHRB | |
| Ether SCHEMBL2801167 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRTHRB | |
| Ether SCHEMBL9688867 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRTHRB | |
| Ether SCHEMBL9321955 | 0.86 | ALDH1A1 (0.56) | ALDH1A1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113447588-A | Method for determining content of peiminine in Huangshi Xiang pill | 无锡济煜山禾药业股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-111714380-B | Heating mask | 武汉世帝牧文化传媒有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-113447588-A | Method for determining content of peiminine in Huangshi Xiang pill | 无锡济煜山禾药业股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-113447588-A | Method for determining content of peiminine in Huangshi Xiang pill | 无锡济煜山禾药业股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20080268044-A1 | Novel Process and Formulations | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| CN-1857594-A | Medicine composition for activating Qi and relieving hyperacidity to alleviate stomacheache and its preparing method and application | ZHENBAODAO PHARMACEUTICAL CO L (CN) | 2006-11-08 | — | — | CN | disclosed |
| EP-0757681-B1 | CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-09-18 | — | — | EP | disclosed |
| US-5834463-A | CONTROLLING FERTILITY, MENSTRUAL CYCLES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0757681-A1 | CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029900-A1 | CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-11-09 | — | — | WO | disclosed |
| EP-0500610-A1 | NUCLEOSIDE DERIVATIVES | NYCOMED IMAGING AS (NO) | 1992-09-02 | — | — | EP | disclosed |
| WO-1991006554-A1 | NUCLEOSIDE DERIVATIVES | NYCOMED AS (NO) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268044-A1 | Novel Process and Formulations | UGT1A7, UGT2B7, CYP3A7 | ALDH1A1 320/4885TSHR 3854/4885THRB 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.